Loading...
01/11 16:22
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reveals significant challenges: a 33.8% revenue decline, a 32.8% drop in active coaches, and a net loss of $800,000. Despite cost reductions, operational losses and weak guidance overshadow any positives. The Q&A highlights management's reluctance to provide clear guidance, adding uncertainty. The absence of a shareholder return plan and a decrease in marketing efforts further dampen outlook. These factors suggest a negative stock price reaction over the next two weeks.
Revenue $115,700,000, a decrease of 33.8% year-over-year, primarily due to a decrease in the number of active earning OPTAVIA Coaches.
Active Earning OPTAVIA Coaches 25,400, a decrease of 32.8% year-over-year.
Average Revenue per Active Earning OPTAVIA Coach $4,556, a decrease of 1.4% year-over-year, an improvement from a 22% decrease in Q1 of 2024, driven by increased productivity of newer coach cohorts.
Gross Profit $84,200,000, a decrease of 33.8% year-over-year, driven by lower sales volumes.
Gross Profit Margin 72.8%, consistent with the year earlier period.
SG&A Expense $85,500,000, a decrease of 28.4% year-over-year, primarily due to a $22,400,000 decrease in OPTAVIA Coach compensation, $3,000,000 decrease in market research and investment costs, $2,500,000 decrease in employee compensation, and $1,300,000 decrease in credit card fees.
Loss from Operations $1,300,000, down $9,200,000 year-over-year, as the decline in gross profit was largely offset by lower SG&A as a percentage of revenue.
Other Income $1,800,000, a decrease of 50.9% year-over-year, due to higher unrealized gains on investments in LifeMD common stock in the prior year.
Income Tax Expense $1,300,000, lower than $3,300,000 in the prior year, primarily driven by a decrease in pre-tax income.
Net Loss $800,000 or $0.07 per share, compared to net income of $8,300,000 or $0.76 per diluted share in the prior year.
Cash and Cash Equivalents $164,600,000, with no interest-bearing debt as of 03/31/2025.
New Product Launches: Launched OPTAVIA Active for individuals wanting to incorporate exercise into their plans and the OPTAVIA Ascend line designed for those using GLP-one medications.
Product Development: Recent breakthroughs in product development are expected to enhance the effectiveness of the OPTAVIA essential line.
Market Positioning: Medifast is focusing on the health and wellness space, particularly around weight loss and weight management, leveraging the growing trend of GLP-one medications.
Market Expansion: The company is enhancing its coaching model to better support clients using GLP-one medications, thus expanding its market reach.
Operational Efficiency: Streamlining the coach development path to simplify the coaching experience and increase productivity.
Cost Management: SG&A expenses decreased by 28.4% year over year, primarily due to reduced OPTAVIA Coach compensation.
Strategic Shift: Shifting focus from company-led marketing to empowering coaches for customer acquisition and retention.
Coaching Strategy: Enhancing tools and insights for coaches to provide personalized customer service and support.
Revenue Decline: Revenue for Q1 2025 was $115.7 million, a decrease of 33.8% year-over-year, primarily due to a decrease in the number of active earning OPTAVIA Coaches.
Active Coaches: The number of active earning OPTAVIA Coaches decreased by 32.8% from Q1 2024, impacting revenue generation.
Economic Factors: A weaker economy could present consumer demand headwinds, although historical trends suggest economic slowdowns may increase coach recruitment as individuals seek additional income opportunities.
Marketing Strategy: The company is reducing company-led marketing efforts, which may impact customer acquisition costs and overall SG&A expenses.
GLP-1 Medication Impact: The introduction of GLP-1 medications has created a need for retraining coaches to adapt to the new market environment, which may disrupt existing coaching practices.
Customer Retention Challenges: Studies indicate that a significant percentage of individuals using GLP-1 medications struggle with long-term weight maintenance, highlighting the need for effective coaching and support.
Operational Loss: The company reported a net loss of $800,000 in Q1 2025, compared to a net income of $8.3 million in the previous year, indicating financial challenges.
SG&A Expenses: SG&A expenses decreased by 28.4% year-over-year, but the percentage of revenue increased due to lower sales volumes, indicating operational inefficiencies.
Focus on Coaches: In 2025, Medifast is sharpening its focus on reigniting the coach community, simplifying the coaching experience, increasing productivity, and enhancing customer acquisition and retention.
Streamlining Coach Development: The company is streamlining the coach development path to empower coaches with clearer guidance and intuitive incentives for business growth.
Enhancing Tools for Coaches: Medifast is enhancing digital tools and insights for coaches to better track customer progress and deliver personalized service.
Broaden Product Offerings: The company is broadening its product offerings, including the OPTAVIA Active and Ascend lines, to better serve customers.
Investment in Development: Investment in product development is expected to be mitigated by reductions in company-led marketing costs.
Q2 Revenue Guidance: Medifast expects second quarter revenue to range from $85 million to $105 million.
Loss Per Share Guidance: Loss per share for the second quarter is expected to range from $0.00 to $0.55.
Long-term Outlook: The company anticipates improvement in coach productivity in the second half of 2025 and coach growth in the second half of 2026.
Revenue Expectations: While Q1 revenue was $115.7 million, a decrease of 33.8% year-over-year, the company sees potential for future improvement.
Financial Position: Medifast maintains a strong balance sheet with $164.6 million in cash and no interest-bearing debt.
Shareholder Return Plan: Medifast has not explicitly mentioned a shareholder return plan, such as a share buyback program or dividend program, during the earnings call.
The earnings call highlighted significant challenges, including a 36.2% revenue decline, increased SG&A expenses, and a net loss, indicating financial strain. Despite optimistic guidance on coach productivity and new programs, economic uncertainties and competition pose risks. The Q&A session revealed unclear management responses, adding to investor concerns. Although there are plans for product evolution and a focus on metabolic health, the lack of immediate positive catalysts and the absence of a market cap suggest a negative stock price movement in the short term.
The earnings call revealed significant challenges: a 37.4% revenue decline, reduced coach productivity, and client acquisition pressures. Despite cost optimizations and no debt, the market faces economic uncertainties and competitive challenges from GLP-1 medications. Q&A insights did not mitigate these concerns, as reliance on GLP-1 was noted. While operational improvements and investment gains led to positive net income, the weak revenue guidance and coach network issues indicate a negative short-term outlook, likely resulting in a stock price decline of -2% to -8%.
The earnings call presents a challenging scenario for Medifast, Inc. with significant declines in revenue, active coaches, and earnings. Despite some cost reduction efforts, the overall financial performance is weak, with missed EPS expectations and a negative outlook. The Q&A session revealed management's inability to provide clear guidance, further contributing to uncertainty. The absence of a share repurchase program and the lack of significant positive catalysts suggest a negative market reaction in the near term.
The earnings call reveals significant challenges: a 33.8% revenue decline, a 32.8% drop in active coaches, and a net loss of $800,000. Despite cost reductions, operational losses and weak guidance overshadow any positives. The Q&A highlights management's reluctance to provide clear guidance, adding uncertainty. The absence of a shareholder return plan and a decrease in marketing efforts further dampen outlook. These factors suggest a negative stock price reaction over the next two weeks.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
